• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.芦可替尼：慢性移植物抗宿主病的类固醇节约剂。
Bone Marrow Transplant. 2018 Jul;53(7):826-831. doi: 10.1038/s41409-017-0081-5. Epub 2018 Jan 24.
2
Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.芦可替尼治疗慢性激素耐药移植物抗宿主病：单中心经验。
Leuk Res. 2021 Oct;109:106642. doi: 10.1016/j.leukres.2021.106642. Epub 2021 Jun 11.
3
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).Ruxolitinib 在移植物抗宿主病（GvHD）中的研究（RIG）：一项多中心、随机的 2 期临床试验，旨在确定 Ruxolitinib 和最佳可用治疗（BAT）在激素难治性急性移植物抗宿主病（aGvHD）中的反应率，与 BAT 相比（NCT02396628）。
BMC Cancer. 2018 Nov 19;18(1):1132. doi: 10.1186/s12885-018-5045-7.
4
Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.芦可替尼作为挽救治疗类固醇难治性慢性移植物抗宿主病的疗效和毒性。
Front Immunol. 2021 Jun 30;12:673636. doi: 10.3389/fimmu.2021.673636. eCollection 2021.
5
Ruxolitinib for treatment of steroid-refractory graft-versus-host disease in adults: a systematic review and meta-analysis.芦可替尼治疗成人激素耐药性移植物抗宿主病的系统评价和荟萃分析。
Expert Rev Hematol. 2020 May;13(5):565-575. doi: 10.1080/17474086.2020.1738214. Epub 2020 Mar 21.
6
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.芦可替尼治疗糖皮质激素难治性慢性移植物抗宿主病。
N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122.
7
Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.芦可替尼治疗儿童造血干细胞移植后激素耐药移植物抗宿主病：高缓解率和可管理的毒性。
Pediatr Hematol Oncol. 2021 May;38(4):331-345. doi: 10.1080/08880018.2020.1868637. Epub 2021 Mar 4.
8
Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience.芦可替尼挽救治疗儿童激素耐药性移植物抗宿主病：单中心经验。
Pediatr Blood Cancer. 2020 Apr;67(4):e28190. doi: 10.1002/pbc.28190. Epub 2020 Jan 25.
9
Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients.芦可替尼作为儿童造血干细胞移植患者类固醇难治性急性移植物抗宿主病的挽救疗法
Biol Blood Marrow Transplant. 2017 Jul;23(7):1122-1127. doi: 10.1016/j.bbmt.2017.03.029. Epub 2017 Mar 23.
10
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.鲁索替尼治疗类固醇难治性移植物抗宿主病：一例报告
J Hematol Oncol. 2016 Aug 8;9(1):67. doi: 10.1186/s13045-016-0298-6.

引用本文的文献

1
Long-term follow-up results of ruxolitinib as salvage therapy for chronic graft-versus-host disease.芦可替尼作为慢性移植物抗宿主病挽救治疗的长期随访结果
Hematol Transfus Cell Ther. 2025 May 11;47(3):103835. doi: 10.1016/j.htct.2025.103835.
2
[Ocular graft versus host disease].[眼部移植物抗宿主病]
Ophthalmologie. 2025 Apr;122(4):321-333. doi: 10.1007/s00347-025-02212-y. Epub 2025 Mar 31.
3
Pulmonary complications of bone marrow transplantation.骨髓移植的肺部并发症。
Breathe (Sheff). 2024 Oct 1;20(3):240043. doi: 10.1183/20734735.0043-2024. eCollection 2024 Oct.
4
Understanding the Needs and Lived Experiences of Patients With Graft-Versus-Host Disease: Real-World European Public Social Media Listening Study.了解移植物抗宿主病患者的需求和生活经历：欧洲真实世界公共社交媒体倾听研究
JMIR Cancer. 2023 Nov 10;9:e42905. doi: 10.2196/42905.
5
Dissecting the regulatory network of transcription factors in T cell phenotype/functioning during GVHD and GVT.解析移植物抗宿主病和移植物抗肿瘤中 T 细胞表型/功能的转录因子调控网络。
Front Immunol. 2023 Jun 27;14:1194984. doi: 10.3389/fimmu.2023.1194984. eCollection 2023.
6
Propensity score matching analysis comparing the efficacy of Ruxolitinib to historical controls in second-line or beyond treatment for chronic GvHD after steroid failure.采用倾向性评分匹配分析比较芦可替尼在类固醇治疗失败后二线或以上治疗慢性移植物抗宿主病的疗效与历史对照。
Bone Marrow Transplant. 2023 Sep;58(9):1024-1032. doi: 10.1038/s41409-023-02020-5. Epub 2023 Jun 26.
7
Dentistry consensus on HSCT - Part III: Special topics - Dentistry on HSCT.造血干细胞移植的牙科共识 - 第三部分：特殊主题 - 造血干细胞移植中的牙科
Hematol Transfus Cell Ther. 2023 Jul-Sep;45(3):379-386. doi: 10.1016/j.htct.2023.04.004. Epub 2023 Jun 6.
8
Role of topical and systemic immunosuppression in aqueous-deficient dry eye disease.局部和全身免疫抑制在水液缺乏性干眼疾病中的作用。
Indian J Ophthalmol. 2023 Apr;71(4):1176-1189. doi: 10.4103/IJO.IJO_2818_22.
9
Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management.慢性移植物抗宿主病。第二部分：疾病活动度分级与治疗管理。
J Am Acad Dermatol. 2024 Jan;90(1):19-36. doi: 10.1016/j.jaad.2022.12.023. Epub 2022 Dec 23.
10
Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD.甲磺酸伊马替尼治疗异体移植后激素难治性慢性移植物抗宿主病的多中心二期研究结果。
Cell Transplant. 2022 Jan-Dec;31:9636897221113789. doi: 10.1177/09636897221113789.

本文引用的文献

1
Baricitinib in Patients with Refractory Rheumatoid Arthritis.巴瑞替尼治疗难治性类风湿关节炎患者的疗效。
N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247.
2
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.芦可替尼用于异基因干细胞移植后对皮质类固醇难治的移植物抗宿主病：一项多中心调查
Leukemia. 2015 Oct;29(10):2062-8. doi: 10.1038/leu.2015.212. Epub 2015 Jul 31.
3
Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.含利妥昔单抗的无皮质类固醇初始治疗慢性广泛性移植物抗宿主病
Biol Blood Marrow Transplant. 2015 Sep;21(9):1576-82. doi: 10.1016/j.bbmt.2015.04.023. Epub 2015 May 16.
4
Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.慢性移植物抗宿主病治疗反应的评估。美国国立卫生研究院慢性移植物抗宿主病临床试验标准共识发展项目：IV。2014年反应标准工作组报告。
Biol Blood Marrow Transplant. 2015 Jun;21(6):984-99. doi: 10.1016/j.bbmt.2015.02.025. Epub 2015 Mar 19.
5
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.美国国立卫生研究院慢性移植物抗宿主病临床试验标准共识发展项目：I. 2014年诊断与分期工作组报告
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1. doi: 10.1016/j.bbmt.2014.12.001. Epub 2014 Dec 18.
6
Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.对JAK1/JAK2进行药物阻断可减轻移植物抗宿主病并保留移植物抗白血病效应。
PLoS One. 2014 Oct 7;9(10):e109799. doi: 10.1371/journal.pone.0109799. eCollection 2014.
7
Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis.体外光分离置换法治疗慢性移植物抗宿主病：一项系统评价和荟萃分析。
Blood Res. 2014 Jun;49(2):100-6. doi: 10.5045/br.2014.49.2.100. Epub 2014 Jun 25.
8
Current issues in chronic graft-versus-host disease.慢性移植物抗宿主病的当前问题
Blood. 2014 Jul 17;124(3):374-84. doi: 10.1182/blood-2014-01-514752. Epub 2014 Jun 9.
9
Are we making progress in GVHD prophylaxis and treatment?GVHD 的预防和治疗是否取得了进展？
Hematology Am Soc Hematol Educ Program. 2012;2012:251-64. doi: 10.1182/asheducation-2012.1.251.
10
IFNγR signaling mediates alloreactive T-cell trafficking and GVHD.IFNγR 信号转导介导同种反应性 T 细胞归巢和移植物抗宿主病。
Blood. 2012 Nov 8;120(19):4093-103. doi: 10.1182/blood-2012-01-403196. Epub 2012 Sep 12.

芦可替尼：慢性移植物抗宿主病的类固醇节约剂。

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.

机构信息

Department of Hematology and Medical Oncology Winship Cancer Institute of Emory, University Atlanta, Atlanta, GA, USA.

Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA.

出版信息

Bone Marrow Transplant. 2018 Jul;53(7):826-831. doi: 10.1038/s41409-017-0081-5. Epub 2018 Jan 24.

DOI:10.1038/s41409-017-0081-5
PMID:29367708
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6041160/
Abstract

Inhibition of the Janus-associated kinases (JAK) with ruxolitinib (RUX) reduces graft-versus-host disease (GVHD) in preclinical and clinical models. In total 19 allograft recipients with moderate/severe steroid-dependent chronic GVHD received RUX as ≥2nd line salvage. RUX was well tolerated, and led to complete/partial resolution of oral (92/7%), cutaneous (82/0%), hepatic (71/28%), gastro-intestinal (75/17%), musculoskeletal (33/67%), pulmonary (0/80%), scleroderma (0/75%), vaginal (0/75%), and ocular (0/100%) chronic GVHD. Overall 18 achieved partial response and 1 complete response according to NIH Consensus Criteria. Responses occurred early and were sustained which enabled discontinuation (68%) or reduction of steroids to physiologic doses (21%). We conclude that RUX is an effective steroid-sparing agent in chronic GVHD.

摘要

抑制 Janus 相关激酶（JAK）的芦可替尼（RUX）可减少临床前和临床模型中的移植物抗宿主病（GVHD）。共有 19 名接受同种异体移植且患有中度/重度类固醇依赖型慢性 GVHD 的患者接受了 RUX 作为二线挽救治疗。RUX 耐受性良好，导致口腔（92/7%）、皮肤（82/0%）、肝脏（71/28%）、胃肠（75/17%）、肌肉骨骼（33/67%）、肺（0/80%）、硬皮病（0/75%）、阴道（0/75%）和眼部（0/100%）慢性 GVHD 完全/部分缓解。根据 NIH 共识标准，18 例患者达到部分缓解，1 例完全缓解。反应发生得早且持续，从而能够停用（68%）或减少类固醇至生理剂量（21%）。我们得出结论，RUX 是慢性 GVHD 中一种有效的类固醇节约剂。